Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610893 | 0.89 | TSHR (0.42) | MAPK1SMN1; SMN2TSHRL3MBTL1ADRA1A | |
| SCHEMBL964686 | 0.87 | TSHR (0.41) | MAPK1SMN1; SMN2TSHRL3MBTL1FFAR4 | |
| SCHEMBL2747320 | 0.86 | HSD11B1 (0.46) | FFAR4 | |
| SCHEMBL13067453 | 0.86 | L3MBTL1 (0.44) | SMN1; SMN2TSHRL3MBTL1FFAR4ALDH1A1 | |
| SCHEMBL16724554 | 0.86 | L3MBTL1 (0.51) | MAPK1SMN1; SMN2TSHRL3MBTL1HDAC3 | |
| SCHEMBL4611767 | 0.83 | LMNA (0.42) | MAPK1SMN1; SMN2TSHRL3MBTL1MAPT | |
| SCHEMBL6158800 | 0.81 | TSHR (0.43) | MAPK1SMN1; SMN2TSHRL3MBTL1OPRM1 | |
| SCHEMBL4612086 | 0.80 | MAPT (0.39) | MAPK1SMN1; SMN2TSHRL3MBTL1MAPT | |
| SCHEMBL16724555 | 0.80 | TSHR (0.40) | MAPK1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL4613715 | 0.79 | TSHR (0.42) | MAPK1SMN1; SMN2TSHRL3MBTL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102356081-A | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2012-02-15 | — | — | CN | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-1294671-B1 | UTILISATION OF KETONES AS PRECURSORS OF ACTIVE COMPOUNDS | FIRMENICH & CIE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-6949680-B2 | Ketones as precursors of active compounds | FIRMENICH SA (CH) | 2005-09-27 | — | — | US | disclosed |
| US-20030129212-A1 | Ketones as precursors of active compounds | FIRMENICH SA (CH) | 2003-07-10 | — | — | US | disclosed |
| EP-1294671-A2 | UTILISATION OF KETONES AS PRECURSORS OF ACTIVE COMPOUNDS | FIRMENICH SA (CH) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096272-A2 | UTILISATION OF KETONES AS PRECURSORS OF ACTIVE COMPOUNDS | FIRMENICH SA (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | MAPK1 3062/4885SMN1; SMN2 871/4885TSHR 4632/4885 |
| US-20030129212-A1 | Ketones as precursors of active compounds | PKN3, PKM, FPR3 | MAPK1 1427/4885SMN1; SMN2 4291/4885TSHR 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.